CanSino Biologics Cash Per Share vs. Return On Asset
| CJH Stock | EUR 3.64 0.02 0.55% |
For CanSino Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of CanSino Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well CanSino Biologics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between CanSino Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of CanSino Biologics over time as well as its relative position and ranking within its peers.
CanSino |
CanSino Biologics Return On Asset vs. Cash Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining CanSino Biologics's current stock value. Our valuation model uses many indicators to compare CanSino Biologics value to that of its competitors to determine the firm's financial worth. CanSino Biologics is rated third in cash per share category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CanSino Biologics' earnings, one of the primary drivers of an investment's value.CanSino Return On Asset vs. Cash Per Share
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
CanSino Biologics |
| = | 27.12 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
CanSino Biologics |
| = | -0.0207 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CanSino Return On Asset Comparison
CanSino Biologics is rated below average in return on asset category among its peers.
CanSino Biologics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in CanSino Biologics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, CanSino Biologics will eventually generate negative long term returns. The profitability progress is the general direction of CanSino Biologics' change in net profit over the period of time. It can combine multiple indicators of CanSino Biologics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the Peoples Republic of China. CANSINO BIOLOGICS operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 726 people.
CanSino Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on CanSino Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of CanSino Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the CanSino Biologics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in CanSino Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
Use Investing Themes to Complement your CanSino Biologics position
In addition to having CanSino Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run ESG Investing Thematic Idea Now
ESG Investing
Sustainable investments that promote the conservation of the natural world, social resposibility, freindly employees policies and strong governance. The ESG Investing theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ESG Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in CanSino Stock
To fully project CanSino Biologics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of CanSino Biologics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include CanSino Biologics' income statement, its balance sheet, and the statement of cash flows.